The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

Lenacapavir, the world's first twice-yearly HIV prevention shot, gets US FDA nod-offering a discreet, long-acting solution ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

Spread This NewsBy Lauran Neergaard I Associated Press THE U.S. has approved the world’s only twice-a-year shot to prevent ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

FDA approval paves the way for the jab to roll out across the world. But with funding being slashed, will it get to the ...

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...

WHO celebrates FDA's nod to injectable lenacapavir for HIV prevention, promising easier adherence with biannual doses.

FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its ...